Meet The Right Outsourced Manufacturing Partner
We have reached a defining moment in our country as the U.S. pharmaceutical industry reexamines the resiliency of global supply chains and looks to augment security through domestic partnerships. Relationships between the nation’s pharmaceutical companies and contract development and manufacturing organizations (CDMOs) are quickly becoming vital bonds, capable of breathing life into the U.S. economy.
But how do pharmaceutical companies find the right domestic partner? What goes into their decision-making? At GRAM, we have found that our domestic partners are looking for a U.S.-based CDMO with the following attributes:
- A strong track record of consistently producing high-quality products. We are proud to say our last two audits resulted in zero FDA Form 483s. FDA-regulations are closely followed to ensure all our equipment and processes are fully qualified and validated for complete cGMP compliance. GRAM’s quality processes come with experience in project management; an area in which we have a wealth of knowledge and a stellar reputation.
- The capacity to handle complex and critical projects. Domestic CDMOs must be equipped to meet increased demand, and it helps if they can demonstrate sustained periods of growth. GRAM has ranked on Inc. Magazine’s Inc. 5000 list of the nation’s fastest-growing private companies for the past four years. This year, we tripled our manufacturing footprint with the addition of a new 60,000+ square foot fill/finish facility, specifically designed to meet the changing needs of the pharmaceutical industry.
- Quality-focused culture. It comes down to the people and whether the values of the two organizations align. For GRAM, flexibility, attention to detail, and unparalleled accountability are traits we bring to the partnership all the while supported by a work environment conducive to long-term prosperity.
GRAM is extremely proud to be in the position to be of service in the pharmaceutical industry and stand ready to answer the calls of many more U.S.-based pharma organizations.